Showing recent highlights
Lifestyle
PubMed · December 31, 2026
This study looked at what happened when overweight college-age women took different amounts of caffeine before doing 40 minutes of moderate-paced treadmill walking — specifically walking at the speed where their bodies burned the most fat. The researchers found that a moderate caffeine dose (roughly 3–5 mg per kilogram of body weight — so about 200–340 mg for a 150-pound person, roughly the amount in 2–3 cups of coffee) taken before that walk increased the amount of fat the body burned during exercise compared to no caffeine, without raising heart rate or blood pressure the way the higher doses did. The evidence is early and was tested in a small group of young women, so it's worth discussing with your doctor before making any changes, especially since caffeine affects everyone differently.
Ask your doctor: Ask the doctor whether drinking caffeine before I exercise might help the patient's body burn more fat during workouts.
What's New
PubMed · December 31, 2026
Researchers found that men with obesity who combined a plant-based supplement called fisetin with a 12-week exercise program — mixing strength training and cardio — showed notable improvements in inflammation and blood sugar control compared to those who only exercised or only took the supplement. Specifically, levels of a natural inflammation-calming molecule in the body called Maresin-1 went up, while markers of inflammation and insulin resistance (a sign the body is struggling to manage blood sugar properly) went down most in the group that did both. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · December 31, 2026
Researchers found that taking a pasteurized probiotic supplement (called Akkermansia muciniphila) for 3 months showed some promising results for people with prediabetes — a condition where blood sugar is higher than normal but not yet at diabetes levels. In particular, people who naturally had low levels of this beneficial gut bacteria to begin with seemed to benefit the most, showing improvements in how well their body responds to insulin (the hormone that manages blood sugar), as well as reductions in body weight and trunk fat. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · December 31, 2026
A study found that a probiotic supplement (called LP5282, made from heat-treated bacteria) helped overweight adults lose weight and body fat — but only in people who started out with less variety of bacteria in their gut. Researchers found that people with a less diverse gut microbiome (the community of bacteria living in the digestive tract) saw meaningful reductions in body weight and a hormone called leptin, which is linked to appetite and fat storage, while people with a more diverse gut microbiome didn't see the same benefits. This suggests that the makeup of a person's gut bacteria might play a role in how well certain weight-related supplements work for them. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · December 31, 2026
Researchers found that when people with obesity and type 2 diabetes received a fecal microbiota transplant — a procedure where gut bacteria from a healthy donor are transferred to another person — changes in the gut's viral community (the collection of viruses naturally living in the digestive system) were just as good as changes in bacteria at predicting who responded well to treatment, particularly in terms of LDL (often called 'bad' cholesterol) levels. This suggests that the viruses living in the gut may play an important role alongside bacteria in how well the body responds to this kind of treatment, which could help explain why some people benefit more than others. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · December 30, 2026
A study found that people who took a supplement called Forcslim for 12 weeks lost about 1.93 kg (roughly 4 pounds) more than those who took a placebo (a dummy pill with no active ingredient), and also saw their waist size shrink by about 1.83 cm. Researchers also found improvements in blood fat levels — specifically, a drop in triglycerides (a type of fat in the blood linked to heart health) and a rise in HDL, often called 'good' cholesterol — with no worrying side effects reported. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · December 30, 2026
Researchers found that overweight and obese women who followed a 4-week exercise program saw reductions in chest and abdominal measurements, along with improvements in reproductive hormones linked to fertility. Adding cinnamon supplements to the exercise routine made a small additional difference in chest size, but did not produce significantly greater changes in belly size or hormone levels compared to exercise alone. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · December 1, 2026
This study compared two weight-loss medications — tirzepatide (brand name Mounjaro or Zepbound) and semaglutide (brand name Wegovy or Ozempic) — in people with obesity or excess weight. Researchers found that tirzepatide not only helped people lose more weight and reduced the risk of serious health problems like serious heart problems like heart attacks or strokes, but it was also estimated to cost less overall when factoring in healthcare and broader life costs. This appears to be a new finding about how these two medications compare, rather than a safety update or guideline change.
Ask your doctor: Ask the doctor whether tirzepatide might work better for the patient's weight loss than semaglutide, since studies show it helped people lose more weight.
What's New
PubMed (Open Access Guidelines) · December 1, 2026
Researchers found that whole-body vibration training — a type of exercise where people stand or move on a platform that vibrates — helped lower resting blood pressure in adults. The effect was especially noticeable in people who already had higher blood pressure or who were overweight, with their top blood pressure number dropping by more than 11 points on average in those groups. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · December 1, 2026
A study found that people with type 2 diabetes and high blood pressure who lost weight through a dietary program — about 25 pounds on average over 12 months — were able to cut back on their high blood pressure medications, yet their blood pressure stayed just as well controlled as before. In fact, their heart rate and certain measures of blood pressure fluctuation during the night also improved. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · December 1, 2026
Researchers found that people with psoriasis who are obese may not respond as well to certain biologic medications — powerful treatments that target the immune system to clear skin — compared to people who are not obese. The difference was most noticeable with two specific types of biologics (those targeting proteins called IL-17 and IL-12/23), while other types did not show the same pattern, though the evidence is still limited. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · December 1, 2026
Researchers found that a compound called sodium pentaborate pentahydrate — a form of boron, a naturally occurring mineral — helped people with obesity or overweight lose a modest amount of body weight over 12 weeks, with the highest dose (1,000 mg) showing the greatest effect compared to a sugar pill. No major safety concerns were flagged during the trial period, which is an encouraging early sign. This is early research and hasn't yet changed treatment guidelines.
What's New
ScienceDaily · November 2, 2026
A study found that carrying extra body weight may speed up brain aging, causing faster declines in memory, focus, and decision-making — especially in people over 65. This large study followed more than 8,200 adults over 24 years, making its findings particularly notable. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 2, 2026
A study found that people with obesity who received more intensive support — including frequent nutrition guidance, diet and exercise coaching, and additional medication — were more likely to see their obesity-related health conditions go away entirely compared to those in a standard care program (about 17% versus 6%), and they also lost more harmful belly fat, even though the difference in overall weight loss between the two groups was small. Interestingly, the intensive group also saw earlier improvements in high blood pressure and reported feeling more motivated to stick with their treatment over time. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
A study found that people with type 2 diabetes and severe obesity who had weight-loss surgery were still experiencing diabetes remission — meaning their blood sugar returned to a healthy range without medication — up to 10 years later. One type of surgery called gastric bypass showed stronger results in the early years, but by the 10-year mark, the differences between surgery types had narrowed. Researchers also looked at which factors best predicted who would stay in remission long-term, which could help doctors and patients make better decisions about surgery. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that a new weekly injection called petrelintide helped people with obesity lose a meaningful amount of body weight over about six months, using a different approach in the body than well-known medications like Ozempic or Victoza. This matters because having more treatment options with different ways of working could eventually help people who don't respond well to existing medications. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
A study found that taking a daily supplement made from whole feijoa fruit (a small green fruit rich in natural plant compounds) did not improve fasting blood sugar — the level of sugar in the blood after not eating overnight — or weight loss beyond what a low-calorie diet alone achieved in people at risk for type 2 diabetes. Both groups in the study did see improvements in blood sugar and body weight, but those taking the feijoa powder did not do better than those taking a placebo, suggesting the diet itself was doing the heavy lifting. For someone with prediabetes, this matters because it hints that feijoa supplements may not add extra benefit on top of a healthy eating plan, though the full picture of results was not yet reported. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that mazdutide, a new once-weekly injection that works similarly to a diabetes medication like Ozempic or Victoza but also targets an additional hormone pathway, helped adults with obesity lose meaningful amounts of weight over about eight months. The drug was tested at several different doses, with higher doses appearing to produce greater weight loss compared to a placebo (an inactive injection). This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that people taking a diabetes medication like Ozempic or Victoza may lose more body fat compared to other treatments, but the findings were mixed and inconsistent across studies. Interestingly, questions remain about whether these medications also affect muscle — both how much muscle people have and how well it functions — which matters because losing muscle along with fat can affect strength and overall health. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · November 1, 2026
A study found that retatrutide — an experimental weight-loss medication not yet widely available — helped improve several markers linked to heart health in people with obesity, both with and without type 2 diabetes. Researchers found it significantly lowered unhealthy fats and cholesterol-related particles in the blood, which are things that can raise a person's risk of serious heart problems like heart attacks or strokes. This appears to be a new and still-investigational option, as the findings come from early-phase trials testing how the drug works in the body.
What's New
PubMed · November 1, 2026
A clinical trial is examining whether tirzepatide — a newer weight-loss injection — helps people with obesity lose weight and avoid developing type 2 diabetes over five years, compared to standard care alone. Researchers found this kind of real-world study, involving about 3,000 people in the UK, could also reveal whether the medication improves quality of life and even helps people stay employed and miss less work due to illness. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that certain weight-loss surgeries — specifically biliopancreatic diversion (BPD) and a variation called BPD with duodenal switch — led to significant, lasting results over 10 or more years, including major weight loss and high rates of improvement in conditions like type 2 diabetes, high blood pressure, and sleep apnea in people with obesity. However, these surgeries also came with meaningful long-term risks, including low iron levels in about 1 in 3 patients, bone problems in 1 in 4, and anemia (a shortage of healthy red blood cells) in nearly 1 in 5 — suggesting that nutritional monitoring would be an important part of long-term care after these procedures. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
A study found that certain weight-loss surgeries — particularly one called one-anastomosis gastric bypass — were significantly better than sleeve gastrectomy (a common procedure that removes part of the stomach) at improving type 2 diabetes and high blood pressure in people with obesity. The study, which analyzed data from over 61,000 patients across 55 studies, also found that sleeve gastrectomy was more likely to cause new acid reflux problems compared to other surgical options. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that for people with a type of heart failure called HFpEF — where the heart pumps normally but doesn't relax well — obesity plays a major role by causing fat buildup around the heart, inflammation, and other changes that make the condition worse. The review found that a diabetes medication like Jardiance or Invokana had the strongest evidence for helping these patients, while medications like Ozempic and a newer drug called tirzepatide also showed promising results in improving symptoms, physical ability, and body weight. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that people living with chronic kidney disease (CKD — a condition where the kidneys gradually lose their ability to filter waste from the blood) and obesity have often struggled with their weight for a long time, and they responded well to a very low-calorie eating plan when they felt supported by a caring, trustworthy care team and a program tailored to their individual needs. The study highlighted that having personalized routines and ongoing encouragement helped people stick with the diet and build lasting habits. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · November 1, 2026
According to updated Korean Medicine Clinical Practice Guidelines, traditional Korean medicine approaches — including herbal medicine, acupuncture, and a technique called auricular acupuncture (where small needles or pressure points are applied to the ear) — are recommended as options for managing obesity, with herbal medicine receiving the strongest level of support. These recommendations focus on practical outcomes like body weight, body mass index (a measure of body size based on height and weight), waist size, and body fat. The guidelines also note that more high-quality research is still needed to better understand how well these treatments work over time.
What's New
PubMed · November 1, 2026
Researchers found that breaking up long periods of sitting with several short, brisk 5-minute walks spread throughout the day was just as effective as one continuous 45-minute walk at increasing the total calories people burned each day — and it was the only approach that actually reduced long, unbroken stretches of sitting time. For people with obesity, this is encouraging because it suggests that fitting in movement in small chunks during a busy day may be just as valuable as a single dedicated workout. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that older adults with obesity who followed a very low-carbohydrate diet (less than 10% of their calories from carbs) for 8 weeks saw a dramatic drop — about 24% — in fat stored between their muscles, compared to just 1% for those on a low-fat diet. This type of fat, tucked between muscle fibers rather than under the skin, is linked to weaker muscles and trouble moving around as people age. The study also found that the more this between-muscle fat decreased, the more grip strength, knee strength, and balance improved — which could be meaningful for older people with obesity who want to stay mobile and independent. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · November 1, 2026
According to International Federation for the Surgery and Other Therapies for Obesity (IFSO) guidelines, weight-loss surgery — which helps people with obesity achieve lasting weight loss — appears to be linked to lower rates of certain cancers, including breast, uterine, and colon cancers, compared to non-surgical weight-loss approaches. The guidelines note that obesity is one of the fastest-growing contributors to cancer risk worldwide, and that sustained weight loss may help reduce that risk. However, IFSO cautions that the current evidence comes from observational studies rather than the most rigorous type of research, so the findings, while promising, are not yet considered definitive.
Ask your doctor: Ask the doctor whether weight loss surgery might help reduce the patient's risk of getting cancer compared to trying to lose weight through diet and exercise alone.
What's New
PubMed · November 1, 2026
Researchers found that a modified weight-loss surgery called sleeve gastrectomy with transit bipartition — which reroutes part of the digestive tract compared to a standard sleeve gastrectomy — led to much less acid reflux (where stomach acid flows back up into the throat, causing heartburn and discomfort) in people with obesity one year after surgery, with only about 3 out of 100 patients developing new reflux compared to about 28 out of 100 with the standard surgery. People who had the modified procedure also lost more weight overall. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.